“Shift Toward Gene Therapy and Long-Acting Treatments”
- One prominent trend in the bleeding disorders treatment market is the growing focus on gene therapy and long-acting factor replacement therapies aimed at providing sustained relief and potential cures for conditions such as hemophilia
- These innovative treatments reduce the frequency of infusions and enhance patients' quality of life by maintaining stable clotting factor levels over extended periods
- For instance, recent approvals of gene therapies for hemophilia A and B demonstrate promising long-term results, reducing or eliminating the need for regular prophylactic treatments
- This shift toward advanced therapeutic modalities is reshaping treatment protocols, improving patient outcomes, and driving significant investment in bleeding disorder research and development
